Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124,936 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma.
Yan T, Huang C, Peng C, Duan X, Ji D, Duan Y, Zhang W, Zhao H, Gao K, Yang X, Zhang L, Cheng J, de Castria TB, Pocha C, Tsilimigras DI, Wu T, Su G, Li Y, Yu L, Lu Y. Yan T, et al. Among authors: zhang l, zhang w. Ann Transl Med. 2023 Jan 31;11(2):109. doi: 10.21037/atm-22-6614. Ann Transl Med. 2023. PMID: 36819518 Free PMC article.
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N, Xue J, Xun Z, Zhang L, Cheng J, Lei J, Sun H, Li Y, Lin J, Xie F, Wang D, Pan J, Hu K, Guan M, Huo L, Shi J, Yu L, Zhou L, Zhou J, Lu Z, Yang X, Mao Y, Sang X, Lu Y, Zhao H. Yang X, et al. Among authors: zhang n, zhang l. Hepatol Int. 2023 Jun;17(3):709-719. doi: 10.1007/s12072-022-10480-y. Epub 2023 Feb 8. Hepatol Int. 2023. PMID: 36753026 Free PMC article.
124,936 results
You have reached the last available page of results. Please see the User Guide for more information.